186 related articles for article (PubMed ID: 24789662)
1. Galectin-3: a modifiable risk factor in heart failure.
de Boer RA; van der Velde AR; Mueller C; van Veldhuisen DJ; Anker SD; Peacock WF; Adams KF; Maisel A
Cardiovasc Drugs Ther; 2014 Jun; 28(3):237-46. PubMed ID: 24789662
[TBL] [Abstract][Full Text] [Related]
2. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.
Yu L; Ruifrok WP; Meissner M; Bos EM; van Goor H; Sanjabi B; van der Harst P; Pitt B; Goldstein IJ; Koerts JA; van Veldhuisen DJ; Bank RA; van Gilst WH; Silljé HH; de Boer RA
Circ Heart Fail; 2013 Jan; 6(1):107-17. PubMed ID: 23230309
[TBL] [Abstract][Full Text] [Related]
3. Personalizing biomarker strategies in heart failure with galectin-3.
Sherwi N; Merali S; Wong K
Future Cardiol; 2012 Nov; 8(6):885-94. PubMed ID: 23176690
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice.
Vergaro G; Prud'homme M; Fazal L; Merval R; Passino C; Emdin M; Samuel JL; Cohen Solal A; Delcayre C
Hypertension; 2016 Mar; 67(3):606-12. PubMed ID: 26781273
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 in heart failure with preserved ejection fraction.
de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 interferes with tissue repair and promotes cardiac dysfunction and comorbidities in a genetic heart failure model.
Vlachou F; Varela A; Stathopoulou K; Ntatsoulis K; Synolaki E; Pratsinis H; Kletsas D; Sideras P; Davos CH; Capetanaki Y; Psarras S
Cell Mol Life Sci; 2022 Apr; 79(5):250. PubMed ID: 35441327
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 in cardiac remodeling and heart failure.
de Boer RA; Yu L; van Veldhuisen DJ
Curr Heart Fail Rep; 2010 Mar; 7(1):1-8. PubMed ID: 20425490
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3, a prognostic marker--and a therapeutic target?
Pereira AR; Menezes Falcão L
Rev Port Cardiol; 2015 Mar; 34(3):201-8. PubMed ID: 25746675
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 and post-myocardial infarction cardiac remodeling.
Meijers WC; van der Velde AR; Pascual-Figal DA; de Boer RA
Eur J Pharmacol; 2015 Sep; 763(Pt A):115-21. PubMed ID: 26101067
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3: a novel mediator of heart failure development and progression.
de Boer RA; Voors AA; Muntendam P; van Gilst WH; van Veldhuisen DJ
Eur J Heart Fail; 2009 Sep; 11(9):811-7. PubMed ID: 19648160
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
Azibani F; Benard L; Schlossarek S; Merval R; Tournoux F; Fazal L; Polidano E; Launay JM; Carrier L; Chatziantoniou C; Samuel JL; Delcayre C
Hypertension; 2012 Jun; 59(6):1179-87. PubMed ID: 22547442
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
[TBL] [Abstract][Full Text] [Related]
13. [Galectin 3--a new biomarker for diagnostics and outcome of chronic heart failure].
Lakomkin SV; Skvortsov AA; Goriunova TV; Masenko VP; Tereshchenko SN
Kardiologiia; 2012; 52(3):45-52. PubMed ID: 22839443
[TBL] [Abstract][Full Text] [Related]
14. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
Gehlken C; Suthahar N; Meijers WC; de Boer RA
Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
[TBL] [Abstract][Full Text] [Related]
16. Regulation of adverse remodelling by osteopontin in a genetic heart failure model.
Psarras S; Mavroidis M; Sanoudou D; Davos CH; Xanthou G; Varela AE; Panoutsakopoulou V; Capetanaki Y
Eur Heart J; 2012 Aug; 33(15):1954-63. PubMed ID: 21525025
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
Sharma UC; Pokharel S; van Brakel TJ; van Berlo JH; Cleutjens JP; Schroen B; André S; Crijns HJ; Gabius HJ; Maessen J; Pinto YM
Circulation; 2004 Nov; 110(19):3121-8. PubMed ID: 15520318
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 in heart failure pathology--"another brick in the wall"?
Lala RI; Puschita M; Darabantiu D; Pilat L
Acta Cardiol; 2015 Jun; 70(3):323-31. PubMed ID: 26226706
[TBL] [Abstract][Full Text] [Related]
19. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.
Lok SI; Nous FM; van Kuik J; van der Weide P; Winkens B; Kemperman H; Huisman A; Lahpor JR; de Weger RA; de Jonge N
Eur J Cardiothorac Surg; 2015 Sep; 48(3):407-15. PubMed ID: 25609773
[TBL] [Abstract][Full Text] [Related]
20. Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.
Carrasco-Sánchez FJ; Páez-Rubio MI
Mol Diagn Ther; 2014 Dec; 18(6):599-604. PubMed ID: 24989720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
